These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

449 related articles for article (PubMed ID: 32559681)

  • 1. Ga-68 DOTA-peptides and F-18 FDG PET/CT in patients with neuroendocrine tumor: A review.
    Evangelista L; Ravelli I; Bignotto A; Cecchin D; Zucchetta P
    Clin Imaging; 2020 Nov; 67():113-116. PubMed ID: 32559681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
    Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle.
    Nilica B; Waitz D; Stevanovic V; Uprimny C; Kendler D; Buxbaum S; Warwitz B; Gerardo L; Henninger B; Virgolini I; Rodrigues M
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1585-92. PubMed ID: 26922350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [
    Nogareda Seoane Z; Mallón Araújo MC; Calatayud Cubes A; Barberán Corral C; Domínguez Novoa Y; Cousillas Castiñeira A; Martínez Lago N; de Matías Leralta JM; Pubul Nuñez V
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2024; 43(3):500011. PubMed ID: 38643835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
    Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
    Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
    Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
    Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG.
    Kayani I; Bomanji JB; Groves A; Conway G; Gacinovic S; Win T; Dickson J; Caplin M; Ell PJ
    Cancer; 2008 Jun; 112(11):2447-55. PubMed ID: 18383518
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Prognostic Value of PET/CT Imaging with Combination of
    Zhang P; Yu J; Li J; Shen L; Li N; Zhu H; Zhai S; Zhang Y; Yang Z; Lu M
    Contrast Media Mol Imaging; 2018; 2018():2340389. PubMed ID: 29681780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.
    Morgat C; Vélayoudom-Céphise FL; Schwartz P; Guyot M; Gaye D; Vimont D; Schulz J; Mazère J; Nunes ML; Smith D; Hindié E; Fernandez P; Tabarin A
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1258-66. PubMed ID: 26819103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
    Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
    J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of Bone Metastases by
    Tian R; Xie Q; Yu F; Du C; Yao X; Zang S; Zhang C; Zhang P; Shao G; Yang Z; Wang F; Yu J
    Contrast Media Mol Imaging; 2022; 2022():1750132. PubMed ID: 36447752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Added value of [
    Yoo J; Kim SH; Jeon SK; Bae JS; Han JK
    Eur Radiol; 2021 Oct; 31(10):7734-7745. PubMed ID: 33787974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vertebral metastases from neuroendocrine tumours: How to avoid false positives on
    Gauthé M; Testart Dardel N; Ruiz Santiago F; Ohnona J; Nataf V; Montravers F; Talbot JN
    Eur Radiol; 2018 Sep; 28(9):3943-3952. PubMed ID: 29532242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined imaging with 68Ga-DOTA-TATE and 18F-FDG PET/CT on the basis of volumetric parameters in neuroendocrine tumors.
    Abdulrezzak U; Kurt YK; Kula M; Tutus A
    Nucl Med Commun; 2016 Aug; 37(8):874-81. PubMed ID: 27096719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
    Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of gallium-68 somatostatin receptor and
    Liu X; Li N; Jiang T; Xu H; Ran Q; Shu Z; Wu J; Li Y; Zhou S; Zhang B
    Hell J Nucl Med; 2020; 23(2):188-200. PubMed ID: 32716410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Well-differentiated gastro-entero-pancreatic neuroendocrine tumors with positive FDG-PET/CT: a retrospective chart review.
    Haidar M; Al Mahmasani L; Chehade L; Elias C; El Jebai M; Temraz S; Charafeddine M; Al Darazi M; Shamseddine A
    Nucl Med Commun; 2023 Jun; 44(6):471-479. PubMed ID: 36897058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors.
    Panagiotidis E; Alshammari A; Michopoulou S; Skoura E; Naik K; Maragkoudakis E; Mohmaduvesh M; Al-Harbi M; Belda M; Caplin ME; Toumpanakis C; Bomanji J
    J Nucl Med; 2017 Jan; 58(1):91-96. PubMed ID: 27516446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.